Bristol-Myers Squibb (BMY)
Develops medicines for cancer, blood disorders, immunology, cardiovascular disease and neuroscience.
Something off on this page? Send us feedback.
Develops and commercializes prescription medicines across oncology, hematology, immunology, cardiovascular disease and neuroscience, led by Eliquis and Opdivo. Most revenue comes from the United States, while growth depends on launches and licensed or acquired assets replacing products exposed to patent expiry and generic or biosimilar competition.
Discovers, develops, licenses, manufactures and sells prescription medicines across oncology, hematology, immunology, cardiovascular disease and neuroscience. The portfolio spans small molecules and biologics, including Opdivo and Yervoy in cancer, Eliquis in cardiovascular care, Orencia and Sotyktu in immunology, Cobenfy in neuroscience, and the CAR-T therapies Breyanzi and Abecma.
Commercial scale, specialist sales teams and dedicated manufacturing for biologics and cell therapies support launches worldwide; the United States supplies most revenue. Business development remains integral, from acquired products and platforms to collaborations such as the Eliquis alliance with Pfizer.
Operates as one biopharmaceutical segment. Revenue depends heavily on a few medicines, while patent expirations, generic and biosimilar entry, regulatory approval, government pricing and reimbursement, and specialized manufacturing govern the portfolio’s economics.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | Piper Sandler | Reiterate | Rating: —Target: $75 | Target: $82 |
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $53 | Target: $65 |
| Aug 5, 2026 | Raymond James | Initiate | Rating: — | |
| Aug 5, 2026 | Roth Capital | Initiate | Rating: —Target: — | Target: $75 |
| Aug 5, 2026 | UBS | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.07B · Total debt $43.12B · Total assets $87.63B · Shareholders' equity $22.32B
- Revenue
- $12.97B
- Operating income
- $4.09B
- Net income
- $3.32B
HistoryDividendAnnual yieldUpcoming
| Institutions | 85.35% | 1.74B shares | |
|---|---|---|---|
| 2,621 holders · as of Jun 30, 2026 | |||
| Insiders | 0.05% | 977.8K shares | |
| 16 holders · as of Sep 10, 2026 | |||
| Other | 14.60% | 298.36M shares | |
| remainder | |||
2.04B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.83% | 180.38M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.53% | 133.34M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.01% | 102.41M | as of Jun 30, 2026 |
JPMorgan Chase & CoInstitution | 3.51% | 71.71M | as of Jun 30, 2026 |
Charles Schwab Investment Management IncInstitution | 3.31% | 67.60M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 9, 2026 | Cristian Massacesi | officer: EVP,Chief Med Offr,Head of Dev | −6,249 | $64.57 |
| Aug 25, 2026 | Phil M. Holzer | officer: SVP and Controller | −500 | $67.50 |
| Apr 1, 2026 | David V. Elkins | officer: EVP, Chief Financial Officer | −30,000 | $61.67 |
- Merck
PD-1 arch-rival; Keytruda vs Opdivo across all major solid-tumor indications.
- Johnson & Johnson
Darzalex dominates myeloma; Carvykti leads Abecma in BCMA CAR-T market share.
- AbbVie
Rinvoq/Skyrizi vs Orencia/Sotyktu; Imbruvica/Venclexta vs BMS hematology.
- Pfizer
Alliance partner on Eliquis; broader oncology and cardiovascular rival.
- Novartis (ADR)
RLT leader (Pluvicto vs RayzeBio); Kymriah vs Breyanzi in CD19 CAR-T.
- AstraZeneca (ADR)
Oncology rival in NSCLC (Tagrisso, Imfinzi) and expanding ADC pipeline.
- Amgen
Lumakras vs Krazati in KRAS G12C; Otezla acquirer; Kyprolis + Enbrel peer.
- Gilead Sciences
Yescarta + Tecartus vs Breyanzi in CD19 CAR-T; anito-cel vs Abecma coming.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | $62.74 | +0.18% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Merck | $151.67 | +1.45% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Johnson & Johnson | $268.29 | −0.44% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| AbbVie | $265.12 | +0.24% | $467.37B | 74.5 | 17.4 | 7.3 | +10.2% |
| Pfizer | $27.89 | +0.52% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Novartis (ADR) | $141.27 | +0.21% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| AstraZeneca (ADR) | $168.48 | +0.23% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Amgen | $409.01 | +4.03% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Gilead Sciences | $152.80 | +1.49% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Median | 31.2 | 17.1 | 5.6 | +6.5% |